Predicta Biosciences
United States
- Cambridge, Massachusetts
- 17/07/2024
- Seed
- $5,200,000
Predicta Biosciences is a precision oncology company integrating cutting edge multiomics and liquid biopsies to develop innovative diagnostic and therapeutic products. Predicta's diagnostic product portfolio removes the burden of bone-marrow biopsies, through small blood-based samples, and enables best-in-class treatment decision-making for immunotherapies. Utilizing the data from the diagnostic platform, Predicta has an in-house therapeutic pipeline of novel immunotherapy targets in pre-clinical discovery and development.
- Industry Biotechnology Research
- Website https://www.predictabiosciences.com/
- LinkedIn https://www.linkedin.com/company/predicta-biosciences/
Related People
Kate (Gallagher) CavesFounder
United States -
Greater Boston
Executive Leader with Business Development, Corporate Development, Marketing and deep technical background in Therapeutic Development and Diagnostic tools. Passionate about the intersection of Biology, Healthcare, and AI.
TIES | $1,500,000 | (Apr 30, 2026)
Certifyde | $2,000,000 | (Apr 30, 2026)
Parallel Web Systems | $100,000,000 | (Apr 30, 2026)
Skyfire | AI | $11,000,000 | (Apr 30, 2026)
General Analysis | $10,000,000 | (Apr 30, 2026)
Fence | $20,000,000 | (Apr 30, 2026)
Tacalyx GmbH | $12,843,270 | (Apr 30, 2026)
OpenObserve | $10,000,000 | (Apr 30, 2026)
Crazy Mountain | $15,000,000 | (Apr 30, 2026)
Windmill(US) | $12,000,000 | (Apr 29, 2026)
Hypervision Surgical | $22,962,410 | (Apr 29, 2026)
Lighthouse Pharmaceuticals | $12,000,000 | (Apr 29, 2026)